Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
暂无分享,去创建一个
R. Burger | H. Gray | C. Aghajanian | R. Debernardo | V. Makker | W. Deng | Y. Collins | Lainie P Martin